Entities / Company
NeoGenomics.
cancer genetics diagnostic testing company based in Fort Myers, Florida, USA
- Reports this week
- 0
- Active events
- 1
- Connections
- 48
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
NeoGenomics operates labs in the US and UK, while both companies provide digital analytics platforms to businesses.Some support1 report
-
Tempus AI and NeoGenomics completed an acquisition to strengthen AI leadership in healthcare.Some support1 report1 development inside
-
NeoGenomics and Zacks Medical operate within the biomedical and genetics sector.Some support1 report
-
William Blair inquired about revised guidance philosophy from NeoGenomics on August 12, 2025.Some support1 report
-
Uncertainty over Trump administration policies is affecting NeoGenomics.Speculative1 report
-
NeoGenomics and Western Digital, companies operating in the US and UK, unveiled an aggressive tariff plan in April 2025.Some support2 reports
-
Marjorie Soper, who is currently Head of Oncology at Merck, was appointed to the NeoGenomics Board of Directors.Speculative1 report
-
Adaptive Biotechnologies and NeoGenomics announced a strategic partnership on June 26, 2025.Speculative1 report
-
Multiple medical device and diagnostics companies are affected by Canadian supply chain integration and trade tensions.Some support1 report
-
QUEST, NeoGenomics, LabCorp, Microsoft, and Apple are being discussed in the context of healthcare providers and enterprise software stocks.Some support4 reports
-
UnitedHealth Group, Myriad Genetics, and NeoGenomics are involved in a situation concerning the cancer diagnostics space and weaknesses in the broader healthcare sector.Some support1 report2 developments inside
-
NeoGenomics announced on August 7, 2025, that it provides specialized cancer diagnostic testing services.Well supported3 reports
-
Jeffrey Sherman made an insider purchase in NeoGenomics on August 8, 2025, signaling confidence in the company's prospects.Some support1 report
-
NeoGenomics CEO Anthony Zook acknowledged the company's revenue miss on August 12, 2025.Some support2 reports
-
NeoGenomics operates laboratories across the United States and the United Kingdom.Well supported8 reports
-
NeoGenomics, headquartered in Fort Myers, Florida, was the subject of a report regarding a strategy selling stock after CEO departure news on September 4, 2025.Some support2 reports1 development inside
-
Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.Well supported3 reports2 developments inside
-
NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around NeoGenomics this week
News at the entities that move NeoGenomics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves NeoGenomics
-
TD Cowen OperationalAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves NeoGenomics
-
Natera OperationalNatera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.Moves NeoGenomics
-
Nvidia OperationalNvidia is expanding its platform deployment across major cloud providers, including Google Cloud and Microsoft Azure.Moves NeoGenomics
-
AstraZeneca StructuralAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves NeoGenomics
-
North Carolina Shared contextMatthew Rutter attended a convention held in North Carolina on June 19, 2026.Moves NeoGenomics
Connections
The 13 strongest of 48, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Natera Operational
NeoGenomics and Natera are engaged in active patent litigation and intellectual property disputes.
-
FDA Structural
NeoGenomics' development and commercialization of companion diagnostic tests are dependent on FDA guidance and approval.
-
TD Cowen Operational
TD Cowen actively provides financial ratings and conducts due diligence on NeoGenomics.
-
Jeffrey Sherman Structural
Jeffrey Sherman holds the formal role of CFO at NeoGenomics.
-
AstraZeneca Structural
A's diagnostic tests are utilized by B for identifying patients eligible for targeted therapy.
-
Nvidia Operational
The relationship functions as a partnership where Nvidia enables NeoGenomics' success in the AI-driven market.
-
North Carolina Shared context
The company's district court was located in the state of North Carolina.
-
Halozyme Therapeutics Mentioned together
Both NeoGenomics and Halozyme Therapeutics are listed as top holdings in a First Trust fund.
Show all 13 connections
-
Corcept Therapeutics Mentioned together
Both companies are noted as major holdings within biotech investment funds.
-
Tenet Healthcare Mentioned together
Both Tenet Healthcare and NeoGenomics are identified as peers within the healthcare providers segment.
-
Fort Myers Shared context
NeoGenomics operates from its headquarters located in the city of Fort Myers.
-
Cambridge Shared context
NeoGenomics operates a laboratory within the city of Cambridge.
-
NGS Mentioned together
The evidence describes NGS's business performance and market factors without detailing a direct relationship with NeoGenomics.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
19 events- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- NeoGenomics operates labs in the US and UK, while both companies provide digital analytics platforms to businesses.
- Tempus AI and NeoGenomics completed an acquisition to strengthen AI leadership in healthcare.
- NeoGenomics and Zacks Medical operate within the biomedical and genetics sector.
- William Blair inquired about revised guidance philosophy from NeoGenomics on August 12, 2025.
- Uncertainty over Trump administration policies is affecting NeoGenomics.
- NeoGenomics and Western Digital, companies operating in the US and UK, unveiled an aggressive tariff plan in April 2025.
- Marjorie Soper, who is currently Head of Oncology at Merck, was appointed to the NeoGenomics Board of Directors.
- Adaptive Biotechnologies and NeoGenomics announced a strategic partnership on June 26, 2025.
- Multiple medical device and diagnostics companies are affected by Canadian supply chain integration and trade tensions.
- QUEST, NeoGenomics, LabCorp, Microsoft, and Apple are being discussed in the context of healthcare providers and enterprise software stocks.
- UnitedHealth Group, Myriad Genetics, and NeoGenomics are involved in a situation concerning the cancer diagnostics space and weaknesses in the broader healthcare sector.
- NeoGenomics announced on August 7, 2025, that it provides specialized cancer diagnostic testing services.
- Jeffrey Sherman made an insider purchase in NeoGenomics on August 8, 2025, signaling confidence in the company's prospects.
- NeoGenomics CEO Anthony Zook acknowledged the company's revenue miss on August 12, 2025.
- NeoGenomics operates laboratories across the United States and the United Kingdom.
- NeoGenomics, headquartered in Fort Myers, Florida, was the subject of a report regarding a strategy selling stock after CEO departure news on September 4, 2025.
- Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
- NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.